香雪XPH品牌怎么样 申请店铺

我要投票 香雪XPH在医疗器械行业中的票数:273 更新时间:2025-06-30
香雪XPH是哪个国家的品牌?「香雪XPH」是 广州市香雪制药股份有限公司 旗下著名品牌。该品牌发源于广东省广州市,由创始人王董在1986年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力香雪XPH品牌出海!将品牌入驻外推网,定制香雪XPH品牌推广信息,可以显著提高香雪XPH产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

香雪XPH怎么样

广州市香雪制药股份有限公司,始于1986年,广东省名牌,药典标准制定者,大中药健康产业领先者,现代化高新技术医药企业


“十里梅花浑似雪,萝岗香雪映朝阳。”诗人郭沫若赋诗赞赏的羊城八景之一“萝岗香雪”, 正是香雪制药的发祥地。1986年萝岗制药厂成立,1997年改制为广州市香雪制药股份有限公司,于2010年在中国深圳证券交易所公开发行股票(IPO)挂牌上市(股票代码:300147)。秉承“厚生、臻善、维新”的经营理念,公司把发展中药和实现中药现代化作为长远发展战略,经多年发展,现已成为拥有自主知识产权、自主品牌、自主创新能力的中药现代化的领军企业和技术企业,形成中药资源开发、中药先进制造、现代物流配送、新药创制的完整产业链。香雪制药先后在广东、北京、山西、四川、重庆、安徽、云南和宁夏等地设立十八间公司并投资兴建大规模的GMP生产基地和GAP药材种植基地,形成了新型中药饮片、中成药、功能健康食品(饮料)、养生保健等产品群所组成的大中药健康产业,在中国创造就业职位一万余个。

数字化中药

香雪制药致力于中药现代化的研究和实践,在中药现代化的关键技术——中成药质量控制技术、现代制剂技术、中药给药途径创新等研究取得丰硕成果及突破。香雪制药建立了以“现代中药指纹图谱质量控制技术”为核心的现代中药集成创新系统,应用指纹图谱质控技术,通过计算机相似度分析系统使得成分复杂的中药质量得到有效控制;应用中药临床循证医学评价方法,通过大样品、多中心的大规模临床数据评价使中药疗效准确与经济。香雪制药引进全球先进的信息管理系统,使中药生产经营、销售服务过程实现全面信息资源管理,对企业资源、供应链、客户关系、节能环保、智能办公等方面完成高度集成,使中药企业管理与大数据时代接轨。


Guangzhou Xiangxue Pharmaceutical Co., Ltd. started in 1986. It is a famous brand in Guangdong Province, a standard maker of Pharmacopoeia, a leader in the health industry of traditional Chinese medicine, and a modern high-tech pharmaceutical enterprise Luogang Xiangxue, one of the eight sceneries in Yangcheng, is the birthplace of Xiangxue pharmaceutical. Luogang pharmaceutical factory was established in 1986, and was restructured into Guangzhou Xiangxue Pharmaceutical Co., Ltd. in 1997. It was listed on the Shenzhen Stock Exchange in 2010 (Stock Code: 300147). Adhering to the business philosophy of "health, perfection and renovation", the company takes the development of traditional Chinese medicine and the modernization of traditional Chinese medicine as its long-term development strategy. After years of development, the company has become a leading enterprise and technical enterprise with independent intellectual property rights, independent brand and independent innovation ability, forming the development of traditional Chinese medicine resources, advanced manufacturing of traditional Chinese medicine, modern logistics and distribution, and the creation of new drugs A complete industrial chain. Xiangxue pharmaceutical has successively set up 18 companies in Guangdong, Beijing, Shanxi, Sichuan, Chongqing, Anhui, Yunnan and Ningxia and invested in the construction of large-scale GMP production base and gap medicine planting base, forming a large traditional Chinese medicine health industry composed of new traditional Chinese medicine pieces, proprietary Chinese medicine, functional health food (beverage), health care and other product groups, creating jobs in China More than 10000. Xiangxue pharmaceutical is committed to the research and practice of the modernization of traditional Chinese medicine, and has made fruitful achievements and breakthroughs in the key technologies of the modernization of traditional Chinese medicine, such as the quality control technology of traditional Chinese medicine, the modern preparation technology, and the innovation of the way of administration of traditional Chinese Medicine. Xiangxue pharmaceutical has established a modern integrated innovation system of traditional Chinese medicine with "modern fingerprint quality control technology" as the core. By using fingerprint quality control technology and computer similarity analysis system, the quality of traditional Chinese medicine with complex components can be effectively controlled. By using the clinical evidence-based medicine evaluation method of traditional Chinese medicine, the quality of traditional Chinese medicine can be effectively controlled through large-scale clinical data evaluation of large samples and multi centers The therapeutic effect is accurate and economical. Xiangxue pharmaceutical introduced the world's advanced information management system to realize the comprehensive information resource management in the process of Chinese medicine production, operation and sales service, and highly integrated the enterprise resources, supply chain, customer relationship, energy conservation and environmental protection, intelligent office, etc., so as to make the Chinese medicine enterprise management in line with the big data era.

本文链接: https://brand.waitui.com/5a03ebbad.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

海康威视:加拿大市场在公司2024年营业收入占比中不足0.3%

36氪获悉,海康威视在互动平台表示,加拿大市场在海康威视2024年营业收入占比中不足0.3%,面对各种政治打压,海康威视会继续努力服务好全球客户,继续为加拿大的客户提供产品和服务,会继续坚定推进国际化,会继续提升全球产品竞争力。

18分钟前

商业航天概念持续走高,博亚精工等多股涨停

36氪获悉,截至发稿,商业航天概念持续走高,博亚精工、凯美特气、利君股份、晨曦航空涨停,七丰精工、国科军工、爱乐达、星辰科技、豪能股份、中兵红箭等跟涨。

18分钟前

美国关税冲击下,日本5月工业产出环比仅增0.5%,远逊于预期

周一公布的政府数据显示,日本5月工业产出增速低于预期,因美国全面加征关税威胁到日本本已脆弱的经济复苏。日本经济产业省的数据显示,5月份工业产出环比增长0.5%,远低于3.5%的市场预期中值。日本经济产业省调查的制造商预计,经季节调整后的6月份工业产出将增长0.3%,7月份将下降0.7%。美国关税的打击可能会破坏日本疲弱的经济复苏。(新浪财经)

18分钟前

中信建投:下半年金价不排除会大幅回撤

36氪获悉,中信建投研报表示,1—4月金价大幅上涨至3500美元,核心是特朗普政策带来的不确定性。在下半年贸易缓和、复苏交易的判断下,黄金的短期利多不算明显,若叠加全球股市走强、俄乌冲突缓和等事件,风险偏好回升,在历史高位的金价不排除大幅回撤。

18分钟前

股票型基金新发规模创近四年同期新高

2025年行至年中,截至6月27日,年内已发行成立661只基金(按基金成立日计算),合计发行份额为5261亿份,平均发行份额为7.96亿份,创历史新低。债券基金发行情况不佳,拖累基金整体发行成绩,与之相反的是股票型基金新发规模则创出近四年同期新高。细分类型中,股票型基金有380只,合计发行份额为1855.32亿份,占新发权益基金的近八成;其新发数量、规模同比分别增长66.67%和179.24%,发行规模达到2022年以来同期新高。这主要得益于指数型基金的贡献:上半年成立366只指数基金,总发行份额为1832.03亿份,占据股票型基金新发规模的绝大部分。(中国基金报)

18分钟前

本页详细列出关于香雪XPH的品牌信息,含品牌所属公司介绍,香雪XPH所处行业的品牌地位及优势。
咨询